The aim of the current study was to prove the potential power of interleukin (IL)-6 antibody to attenuate vasospasm after bleeding in a cerebral artery model.Methods
Group 1 (n=10) consisted of normal controls; group 2 (n=20) underwent microsurgical exposure of the atlantooccipital membrane and saline injection into the cisterna magna; and the remaining 40 rats were subjected to blood injection into the cisterna magna. Each of these 40 rats was randomly assigned to either the blood-injection only group (group 3, n=20) or the blood injection plus IL-6 antibody treatment group (group 4, n=20). Half of the rats from each of groups 2, 3, and 4 were killed on Day 2 and the other half on Day 5 after injection, and the inner diameters of the basilar artery and the middle cerebral artery were measured under a surgical microscope.Results
Two doses (10 μg) of IL-6 antibody did not affect the diameter of the middle cerebral artery and the basilar artery when testing was performed on Day 2 after subarachnoid hemorrhage (SAH). On the other hand, administering 5 doses (25 μg) of IL-6 antibody resulted in a significant increase in the diameter of the arteries compared with that seen in the untreated subgroup on Day 5 after SAH.Conclusions
Parenteral multiple delayed dosing of IL-6 antibody is of benefit to attenuate vasospasm after SAH in the rat cerebral artery model, and future parenteral delayed dosing studies are needed to prove the potential power of IL-6 antibody in a cerebral vasospasm model.